A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...

Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s ...

Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and ...

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.” ...

An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on ...

One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform ...

The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...